EN
Cis-DDP is an <antitumor drug> with activity against various <human tumors>. It is generally accepted that <DNA> is the <cellular target> of cis-DDP. The present paper describes the binding models of cis-DDP to DNA, structural distortion in DNA induced by covalent binding of cis-DDP and repair studies of Pt-DNA adducts in pro- and eucariotic systems. We also discuss the possible mechanisms of acquired <resistance> of <cancerous cells> to cis-DDP and analoques, and potential clinical implication of this fenomenon.